Pfizer (PFE)
24.36
-0.30 (-1.23%)
NYSE · Last Trade: Nov 4th, 1:33 PM EST
Detailed Quote
| Previous Close | 24.66 |
|---|---|
| Open | 24.39 |
| Bid | 24.35 |
| Ask | 24.36 |
| Day's Range | 24.31 - 25.20 |
| 52 Week Range | 20.92 - 28.14 |
| Volume | 108,491,968 |
| Market Cap | 136.56B |
| PE Ratio (TTM) | 12.96 |
| EPS (TTM) | 1.9 |
| Dividend & Yield | 1.720 (7.06%) |
| 1 Month Average Volume | 59,978,373 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Tuesday's session.
Via Chartmill · November 4, 2025
Pfizer (PFE) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 4, 2025
Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid.
Via Investor's Business Daily · November 4, 2025
Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Risestocktwits.com
Via Stocktwits · November 4, 2025
Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.
Via Stocktwits · November 4, 2025
Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.87 per share was 37% above analysts’ consensus estimates.
Via StockStory · November 4, 2025
Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.
Via Benzinga · November 4, 2025
Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.
Via The Motley Fool · November 4, 2025
Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance of $9.44 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.70 per share was 4.8% above analysts’ consensus estimates.
Via StockStory · November 4, 2025
Pfizer beat third-quarter expectations Tuesday, though both sales and profit fell year over year. The company also hiked its profit view.
Via Investor's Business Daily · November 4, 2025
Pfizer Q3 2025 earnings beat estimates and the company raised its full-year profit guidance, highlighting strong cost management and non-COVID portfolio growth.
Via Chartmill · November 4, 2025
The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027.
Via Stocktwits · November 4, 2025
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS.
By Pfizer Inc. · Via Business Wire · November 4, 2025
Pfizer reported Q3 2025 revenue of $16.7 billion and adjusted EPS of $0.87, beating expectations and prompting a full-year EPS guidance raise.
Via Talk Markets · November 4, 2025
With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies.
Via The Motley Fool · November 4, 2025
Via Benzinga · November 4, 2025
Stock futures trading lower, watch Uber, Upwork, AMD, Starbucks, Pfizer earnings. Starbucks forms China JV. Cramer advises against AT&T.
Via Benzinga · November 4, 2025
Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, among others.
Via Benzinga · November 3, 2025
November 3, 2025 – The U.S. stock markets are experiencing a significant surge today, with both the S&P 500 and Nasdaq Composite pushing towards new highs. This bullish sentiment is largely fueled by two monumental corporate announcements: a strategic $38 billion partnership between Amazon Web Services (AWS) and OpenAI,
Via MarketMinute · November 3, 2025
These two leading drugmakers are fighting over a promising GLP-1 candidate.
Via The Motley Fool · November 3, 2025
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · November 3, 2025
Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.
Via Investor's Business Daily · November 3, 2025